Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.53 |
| ▸ | STK17B | O94768 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 9/20 | 0.50 |
| ▸ | CDK2 | P24941 | 8/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | IGF1R | P08069 | 2/20 | 0.47 |
| ▸ | CDK4 | P11802 | 2/20 | 0.46 |
| ▸ | CDK7 | P50613 | 2/20 | 0.46 |
| ▸ | CDK9 | P50750 | 2/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCNH | P51946 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4027058 | 0.83 | CDK1 (0.73) | STK17ASTK17BCDK1CDK2CCNB1 | |
| SCHEMBL13648517 | 0.82 | CDK1 (0.55) | CDK1CDK2CCNB1CCNE1CA2 | |
| SCHEMBL1774326 | 0.81 | CDK1 (0.69) | CDK1CDK2CCNB1CCNE1CA2 | |
| SCHEMBL1774325 | 0.81 | CDK1 (0.69) | CDK1CDK2CCNB1CCNE1CA2 | |
| SCHEMBL14112874 | 0.80 | CDK1 (0.68) | CDK1CDK2CCNB1CCNE1CA2 | |
| SCHEMBL2936141 | 0.80 | IGF1R (0.76) | STK17ACDK1CDK2CCNB1CCNE1 | |
| SCHEMBL4061169 | 0.80 | CA2 (0.70) | STK17ASTK17BCDK1CDK2CCNB1 | |
| SCHEMBL13648522 | 0.80 | IGF1R (0.53) | STK17AIGF1RMAPTKMT2ATNK2 | |
| SCHEMBL13648505 | 0.79 | CDK1 (0.55) | CDK1CDK2CCNB1CCNE1CA2 | |
| SCHEMBL14112837 | 0.79 | CDK1 (0.65) | STK17ASTK17BCDK1CDK2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943629-B2 | Anticancer/antitumor agents; S-(4-([4-([(1R,2R)-2-Hydroxy-1-methylpropyl]amino)-5-(trifluoromethyl)-pyrimidin-2-yl]amino)phenyl)-S-methyl-N-[(trifluoromethyl)sulphonyl]-sulphimide for example | BAYER SCHERING PHARMA AG (DE) | 2011-05-17 | — | — | US | disclosed |
| US-7943629-B2 | Anticancer/antitumor agents; S-(4-([4-([(1R,2R)-2-Hydroxy-1-methylpropyl]amino)-5-(trifluoromethyl)-pyrimidin-2-yl]amino)phenyl)-S-methyl-N-[(trifluoromethyl)sulphonyl]-sulphimide for example | BAYER SCHERING PHARMA AG (DE) | 2011-05-17 | — | — | US | disclosed |
| US-7943629-B2 | Anticancer/antitumor agents; S-(4-([4-([(1R,2R)-2-Hydroxy-1-methylpropyl]amino)-5-(trifluoromethyl)-pyrimidin-2-yl]amino)phenyl)-S-methyl-N-[(trifluoromethyl)sulphonyl]-sulphimide for example | BAYER SCHERING PHARMA AG (DE) | 2011-05-17 | — | — | US | disclosed |
| EP-2029552-B1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2010-09-22 | — | — | EP | disclosed |
| EP-2029552-B1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2010-09-22 | — | — | EP | disclosed |
| EP-2029552-A1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | Bayer Schering Pharma AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| WO-2007140957-A1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007140957-A1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | PRKCE, BRAF, PACSIN2 | STK17A 87/4885STK17B 100/4885CDK1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.